"Mary Crowley Cancer Research is a nonprofit 501(c)3 cancer research center that conducts clinical trial testing of the newest cancer discoveries, operating in compliance with the Food and Drug Administration (FDA) guidelines for over 20 years. Mary Crowley offers: • A personalized approach to cancer research • Phase I and Phase II clinical trials matched to molecular information found within each cancer patient •Qualified Physician Investigators who add to the understanding of what drives cancer and create innovative research applications that attack these drivers •A patient-centric focus bringing clinical trial options to patients at a rapid pace"

During the past decade, Mary Crowley Cancer Research conducted 166 clinical trials. In the 10-year time frame, 166 clinical trials started and 52 clinical trials were completed, i.e. on average, 31.3% percent of trials that started reached the finish line to date. In the past 5 years, 96 clinical trials started and 31 clinical trials were completed. i.e. 32.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Mary Crowley Cancer Research" #1 sponsor was "Gradalis, Inc." with 11 trials, followed by "ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 7 trials sponsored, "Point Therapeutics" with 6 trials sponsored, "Astellas Pharma Global Development, Inc." with 5 trials sponsored and "Gilead Sciences" with 5 trials sponsored. Other sponsors include 247 different institutions and companies that sponsored additional 168 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Mary Crowley Cancer Research" #1 collaborator was "Merck Sharp & Dohme LLC" with 13 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 4 trials as a collaborator, "AstraZeneca" with 3 trials as a collaborator, "IQVIA Biotech" with 2 trials as a collaborator and "ADIR, a Servier Group company" with 1 trials as a collaborator. Other collaborators include 27 different institutions and companies that were collaborators in the rest 37 trials.

According to Clinical.Site data, the most researched conditions in "Mary Crowley Cancer Research" are "Ovarian Cancer" (25 trials), "Melanoma" (24 trials), "Pancreatic Cancer" (20 trials), "Colorectal Cancer" (19 trials) and "Solid Tumor" (19 trials). Many other conditions were trialed in "Mary Crowley Cancer Research" in a lesser frequency.

Most popular intervention types in "Mary Crowley Cancer Research" are "Drug" (235 trials), "Biological" (68 trials), "Other" (7 trials), "Genetic" (6 trials) and "Combination Product" (3 trials). Other intervention types were less common.

The name of intervention was led by "Pembrolizumab" (21 trials), "Gemcitabine" (10 trials), "Placebo" (10 trials), "Docetaxel" (7 trials) and "Nivolumab" (7 trials). Other intervention names were less common.

The vast majority of trials in "Mary Crowley Cancer Research" are 259 trials for "All" genders, 15 trials for "Female" genders and 12 trials for "Male" genders.

Currently, there are NaN active trials in "Mary Crowley Cancer Research". 1 are not yet recruiting, 77 are recruiting, 33 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 117 completed trials in Mary Crowley Cancer Research, undefined suspended trials, and 43 terminated clinical trials to date.

Out of the total trials that were conducted in Mary Crowley Cancer Research, 187 "Phase 1" clinical trials were conducted, 137 "Phase 2" clinical trials and 26 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".

Mary Crowley Cancer Research has several departments that took part in Clinical trials: "Mary Crowley Cancer Research Centers - Medical City" - 12 trials